{"product_id":"tenascin-c-antibody-bha17112269","title":"Tenascin C Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eTenascin C Antibody is a research-use primary antibody intended for detection of \u003cstrong\u003eTENASCIN\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003ePurified\u003c\/strong\u003e format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone T2H5, isotype Mouse IgG1, kappa. Applications listed for this product include IHC-P. Reported\/annotated localization context: Connective tissue matrix. Species reactivity (as provided): Human.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e TENASCIN (Tenascin C) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Mouse, Monoclonal (mouse origin), clone T2H5, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Connective tissue matrix — expected subcellular distribution can guide band\/structure interpretation and help flag off-target signal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e In Western blotting, it reacts with two bands of ~MW of 210kDa and 300kDa, identified as two isoforms of Tenascin C. Specificity of this mAb is validated by sequential immunoprecipitation with a PAb against Tenascin C. Tenascin C is a multifunctional, disulfide-linked hexameric extracellular matrix glycoprotein expressed in association with mesenchymal epithelial interactions during development and in the neo-vasculature and stroma of undifferentiated tumors. In adults, it is restricted to certain epithelial-stromal interfaces and increases markedly in hyper-proliferative diseases and in stroma of many neoplasms, including gliomas, breast, squamous and lung carcinomas.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, TENASCIN is positioned within \u003cstrong\u003eMolecular \u0026amp; Cellular Biology, Tumor\u003c\/strong\u003e research contexts. Localization annotations (e.g., Connective tissue matrix) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e IHC on FFPE tissue, ELISA binding assay, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Detect TENASCINC by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to TENASCINC peptide\/protein by ELISA with dilution series (include blanks), Confirm specificity using KO\/KD or…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 100 ug","offer_id":53044896596333,"sku":"V2602-100UG","price":559.0,"currency_code":"USD","in_stock":true},{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 20 ug","offer_id":53044982514029,"sku":"V2602-20UG","price":259.0,"currency_code":"USD","in_stock":true},{"title":"Prediluted in 1X PBS, 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide; *For IHC use only* \/ 7 ml","offer_id":53044982546797,"sku":"V2602IHC-7ML","price":559.0,"currency_code":"USD","in_stock":true},{"title":"1 mg\/ml in 1X PBS; BSA free, sodium azide free \/ 100 ug","offer_id":53044982579565,"sku":"V2602SAF-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_276b750e-cf7c-44ba-ab1e-91fdce3baa9f.jpg?v=1782236804","url":"https:\/\/www.ebiohippo.com\/products\/tenascin-c-antibody-bha17112269","provider":"BioHippo","version":"1.0","type":"link"}